TGF-β plays an important anti-inflammatory role in several settings, including in the blood vessel wall, and interference with TGF-β activity using neutralizing antibodies or genetic manipulation has been shown to increase vascular inflammation in mouse models of atherosclerosis and diabetic kidney disease [76,77,78,79]. This evidence concerns the gene TGFB1 and atherosclerosis.